Escitalopram and Aortic arteriosclerosis - a phase IV clinical study of FDA data

Summary:

Aortic arteriosclerosis is reported as a side effect among people who take Escitalopram (escitalopram oxalate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Aranesp, and have High blood pressure.

The phase IV clinical study analyzes which people have Aortic arteriosclerosis when taking Escitalopram. It is created by eHealthMe based on reports of 75,134 people who have side effects when taking Escitalopram from the FDA, and is updated regularly.

What is Escitalopram?

Escitalopram has active ingredients of escitalopram oxalate. It is often used in depression. eHealthMe is studying from 78,080 Escitalopram users. Check the latest studies of Escitalopram.

What is Aortic arteriosclerosis?

Aortic arteriosclerosis (hardening of the aortic arteries) is found to be associated with 758 drugs and 559 conditions by eHealthMe. Check the latest studies of Aortic arteriosclerosis.

On Jul, 19, 2026

75,134 people reported to have side effects when taking Escitalopram.
Among them, 13 people (0.02%) have Aortic arteriosclerosis.

Could Escitalopram cause Aortic arteriosclerosis?

Among these 13 people:

How long have people been on Escitalopram when they have Aortic arteriosclerosis? *

What is the gender of people who have Aortic arteriosclerosis when taking Escitalopram? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Aortic arteriosclerosis when taking Escitalopram? *

What are other drugs people take besides Escitalopram? *

What are other side effects people have besides Aortic arteriosclerosis? *

Acute Kidney Failure: 4 people, 30.77%
Weakness: 4 people, 30.77%
Weight Decreased: 3 people, 23.08%
Urinary Tract Infection: 3 people, 23.08%
Anaemia (lack of blood): 3 people, 23.08%
Hepatic Steatosis (fatty liver disease): 3 people, 23.08%
Tricuspid Valve Incompetence (inefficient heart valve): 3 people, 23.08%
Thrombocytopenia (decrease of platelets in blood): 3 people, 23.08%
Hepatic Lesion: 3 people, 23.08%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 23.08%

What are the existing conditions these people have? *

Urinary Tract Infection: 2 people, 15.38%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 15.38%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 15.38%
Cardiac Failure Acute: 2 people, 15.38%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 15.38%
Diarrhea: 2 people, 15.38%
Erysipelas (bacterial skin infection): 2 people, 15.38%
Essential Thrombocythaemia (chronic blood cancer): 2 people, 15.38%
High Blood Cholesterol: 2 people, 15.38%
High Blood Pressure: 2 people, 15.38%

* Approximation only. Some reports may have incomplete information.

Do you take Escitalopram and have Aortic arteriosclerosis?

- Check whether Aortic arteriosclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Escitalopram:

Escitalopram (78,080 reports)

Browse all side effects of Escitalopram:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Aortic arteriosclerosis:

Aortic arteriosclerosis (758 drugs)

Browse all the conditions that are associated with Aortic arteriosclerosis:

Aortic arteriosclerosis (559 conditions)

Related publications that referenced our studies

O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on escitalopram oxalate (the active ingredients of Escitalopram) and Escitalopram (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.